Literature DB >> 26101565

Selective Acetamidine-Based Nitric Oxide Synthase Inhibitors: Synthesis, Docking, and Biological Studies.

Cristina Maccallini1, Monica Montagnani2, Roberto Paciotti1, Alessandra Ammazzalorso1, Barbara De Filippis1, Mauro Di Matteo1, Sara Di Silvestre3, Marialuigia Fantacuzzi1, Letizia Giampietro1, Maria A Potenza2, Nazzareno Re1, Assunta Pandolfi3, Rosa Amoroso1.   

Abstract

N-[(3-Aminomethyl)benzyl]acetamidine derivatives were synthesized and in vitro evaluated as inhibitors of the inducible isoform of nitric oxide synthase (iNOS). Because of the high potency of action and the excellent selectivity over the endothelial nitric oxide synthase (eNOS), compound 10 was ex vivo evaluated on isolated and perfused resistance arteries. The results confirm that compound 10 selectively inhibits the iNOS, without affecting the endothelial isoform. The outcome of the docking studies showed that the hydrophobic interaction is the driving force of the binding process, especially for iNOS, where the binding pocket is characterized by a significant lipophilic region.

Entities:  

Keywords:  Acetamidine; inhibitor; molecular docking; nitric oxide synthases; selective; synthesis

Year:  2015        PMID: 26101565      PMCID: PMC4468396          DOI: 10.1021/acsmedchemlett.5b00149

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

1.  Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors.

Authors:  Haitao Ji; Huiying Li; Mack Flinspach; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2003-12-18       Impact factor: 7.446

Review 2.  Nitric oxide in inflammatory bowel disease.

Authors:  Raymond K Cross; Keith T Wilson
Journal:  Inflamm Bowel Dis       Date:  2003-05       Impact factor: 5.325

3.  Hyporeactivity of mesenteric vascular bed in endotoxin-treated rats.

Authors:  D Mitolo-Chieppa; M Serio; M A Potenza; M Montagnani; G Mansi; S Pece; E Jirillo; J C Stoclet
Journal:  Eur J Pharmacol       Date:  1996-08-08       Impact factor: 4.432

4.  Mechanism of inactivation of inducible nitric oxide synthase by amidines. Irreversible enzyme inactivation without inactivator modification.

Authors:  Yaoqiu Zhu; Dejan Nikolic; Richard B Van Breemen; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2005-01-26       Impact factor: 15.419

Review 5.  Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.

Authors:  Ulrich Förstermann; Huige Li
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 6.  Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases?

Authors:  Alan C Tinker; Alan V Wallace
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

7.  N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.

Authors:  Cristina Maccallini; Antonia Patruno; Fabio Lannutti; Alessandra Ammazzalorso; Barbara De Filippis; Marialuigia Fantacuzzi; Sara Franceschelli; Letizia Giampietro; Simona Masella; Mario Felaco; Nazzareno Re; Rosa Amoroso
Journal:  Bioorg Med Chem Lett       Date:  2010-09-17       Impact factor: 2.823

Review 8.  Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications.

Authors:  Li Zhou; Dong-Ya Zhu
Journal:  Nitric Oxide       Date:  2009-03-17       Impact factor: 4.427

9.  Synthesis, biological evaluation, and docking studies of N-substituted acetamidines as selective inhibitors of inducible nitric oxide synthase.

Authors:  Cristina Maccallini; Antonia Patruno; Neva Besker; Jamila Isabella Alì; Alessandra Ammazzalorso; Barbara De Filippis; Sara Franceschelli; Letizia Giampietro; Mirko Pesce; Marcella Reale; Maria L Tricca; Nazzareno Re; Mario Felaco; Rosa Amoroso
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 10.  Role of peroxynitrite in the cardiovascular dysfunction of septic shock.

Authors:  Lucas Liaudet; Nathalie Rosenblatt-Velin; Pal Pacher
Journal:  Curr Vasc Pharmacol       Date:  2013-03-01       Impact factor: 2.719

View more
  5 in total

1.  Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.

Authors:  Cristina Maccallini; Fabio Arias; Marialucia Gallorini; Pasquale Amoia; Alessandra Ammazzalorso; Barbara De Filippis; Marialuigia Fantacuzzi; Letizia Giampietro; Amelia Cataldi; María Encarnación Camacho; Rosa Amoroso
Journal:  ACS Med Chem Lett       Date:  2020-06-19       Impact factor: 4.345

2.  Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.

Authors:  Pasquale Linciano; Barbara De Filippis; Alessandra Ammazzalorso; Pasquale Amoia; Felisa Cilurzo; Marialuigia Fantacuzzi; Letizia Giampietro; Cristina Maccallini; Charlotte Petit; Rosa Amoroso
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

3.  Acetamidine-Based iNOS Inhibitors as Molecular Tools to Counteract Inflammation in BV2 Microglial Cells.

Authors:  Silvia Grottelli; Rosa Amoroso; Lara Macchioni; Fiorella D'Onofrio; Katia Fettucciari; Ilaria Bellezza; Cristina Maccallini
Journal:  Molecules       Date:  2020-06-06       Impact factor: 4.411

4.  Involvement of NOS2 Activity on Human Glioma Cell Growth, Clonogenic Potential, and Neurosphere Generation.

Authors:  Paola Palumbo; Francesca Lombardi; Giuseppe Siragusa; Soheila Raysi Dehcordi; Sabino Luzzi; AnnaMaria Cimini; Maria Grazia Cifone; Benedetta Cinque
Journal:  Int J Mol Sci       Date:  2018-09-17       Impact factor: 5.923

5.  A Novel Prodrug of a nNOS Inhibitor with Improved Pharmacokinetic Potential.

Authors:  Cristina Maccallini; Lisa Marinelli; Patrick Indorf; Ivana Cacciatore; Marialuigia Fantacuzzi; Bernd Clement; Antonio Di Stefano; Rosa Amoroso
Journal:  ChemMedChem       Date:  2020-10-21       Impact factor: 3.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.